+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 16 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating HLX22 combined with trastuzumab and chemotherapy as a first-line treatment for patients with HER2-positive locally advanced or metastatic adenocarcinoma of the gastric or gastroesophageal junction. This phase 3, randomized, double-blind study compares this combination against trastuzumab plus chemotherapy with or without pembrolizumab. The trial aims to assess the efficacy and safety of adding HLX22 in this patient population. Participants will be randomly assigned in a 11 ratio to either the experimental group receiving HLX22 15 mgkg plus trastuzumab and chemotherapy XELOX with or without a placebo for pembrolizumab every three weeks, or the control group receiving placebo for HLX22 plus trastuzumab and chemotherapy XELOX with or without pembrolizumab also every three weeks. Treatment continues until clinical benefit is lost, intolerable side effects occur, death, withdrawal, or other protocol-specified reasons. Throughout the study, participants will have their disease progression monitored by an independent radiology review committee using RECIST v1.1 criteria for up to five years, along with overall survival and response rates. Safety will be regularly assessed by tracking adverse events. The study includes multiple assessments to evaluate treatment effects, and participants will be followed for long-term outcomes during the trial period.

Age: 18Years +All GendersPhase 3
208 locations
R

Actively Recruiting

This clinical trial is designed to compare the duration participants remain free of disease progression when treated with two different combinations of therapies for adults with KRASNRAS and BRAF wild-type unresectable or metastatic left-sided colorectal cancer. The study focuses on how amivantamab combined with chemotherapy compares to cetuximab combined with chemotherapy in treating this specific cancer type. Participants will be divided into two groups. One group receives amivantamab combined with chemotherapy, either mFOLFOX6 containing 5-fluorouracil, leucovorin calcium or levoleucovorin, and oxaliplatin or FOLFIRI containing 5-fluorouracil, leucovorin calcium or levoleucovorin, and irinotecan hydrochloride. The other group receives cetuximab combined with the same chemotherapy options. Treatments are given in 28-day cycles and continue until the cancer progresses or other reasons require stopping the treatment. Throughout the study, participants will undergo regular evaluations to monitor how long they remain without disease progression, assessed by independent review and investigators. Other assessments include overall survival, response rates, duration of response, quality of life questionnaires, and safety monitoring up to several years. The study spans several years, with primary outcomes measured up to over four years and additional follow-up extending beyond seven years to gather comprehensive data on treatment effects and patient well-being.

Age: 18Years +All GendersPhase 3
239 locations
R

Actively Recruiting

Researchers are evaluating zipalertinib, a new EGFR tyrosine kinase inhibitor TKI, compared to a placebo in people with early stage non-small cell lung cancer NSCLC who have uncommon EGFR mutations and have had their tumors completely surgically removed. The study focuses on participants with specific uncommon EGFR mutations, including exon 20 insertions and others in exons 18-21, aiming to understand the treatments impact on disease-free survival after surgery. Participants are randomly assigned to receive either zipalertinib or a matching placebo, both taken orally twice daily. Treatment continues until certain criteria for stopping are met. An independent committee will monitor safety during the study. The study plans to include about 360 participants and will last up to 5 years for measuring outcomes. Throughout the trial, participants will be closely monitored with brain imaging before starting treatment to ensure no brain metastases. Researchers will assess disease-free survival as their main outcome over up to 5 years, along with overall survival and quality of life measures. Safety will be evaluated through tracking adverse events, lab tests, vital signs, heart function via ECG and scans, and quality of life questionnaires. Participants will have regular visits for treatment and assessment over the study period.

Age: 18Years +All GendersPhase 3
253 locations
R

Actively Recruiting

Researchers are evaluating the safety and effectiveness of Pumitamig combined with chemotherapy compared to Nivolumab combined with chemotherapy in people who have not received prior treatment for advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma. This phase 23 randomized study aims to better understand treatment options for these types of cancer. Participants will receive specified doses of Pumitamig or Nivolumab along with chemotherapy drugs such as Folfox or Capox on scheduled days. The study includes multiple experimental treatment arms and uses a double-blind method to compare these combinations. Treatment and evaluations will continue for up to several years, including a primary outcome measurement period lasting up to 2 to almost 4 years. Throughout the study, participants will undergo regular assessments to monitor tumor response, progression-free survival, overall survival, and other cancer control measures using standardized criteria like RECIST v1.1. These evaluations include investigator assessments and blinded independent reviews. Safety and dosing recommendations will also be closely monitored. Participants may expect frequent visits and follow-ups over the course of the study, which lasts several years from enrollment to outcome measurement.

Age: 18Years +All GendersPhase 2Phase 3
161 locations
A

Actively Recruiting

Researchers are evaluating ibuzatrelvir to determine its effectiveness and safety in treating adults and adolescents aged 12 and older who have COVID-19 but are not hospitalized. The study focuses on individuals at high risk of progressing to severe illness. Participants will be randomly assigned to receive either ibuzatrelvir or a placebo, alongside standard care as available locally, with the study lasting approximately six months. Participants will receive either ibuzatrelvir tablets or placebo tablets orally every 12 hours for five days. This is a randomized, double-blind, phase 3 study comparing the investigational drug to placebo. The study allows co-administration of locally available standard treatments. The treatment period is followed by monitoring to assess outcomes related to COVID-19 progression and symptom resolution. During the study, participants will be observed for emergency department visits, hospitalizations, mortality, symptom resolution, and viral load changes over 28 days and up to 24 weeks. Researchers will collect data on medical events, including cardiovascular, renal, and pulmonary complications, as well as Long COVID symptoms. Safety is monitored through adverse event tracking. Overall participation lasts about six months with multiple assessments during this time.

Age: 12Years +All GendersPhase 3
256 locations
E

Actively Recruiting

Researchers are evaluating the effects of therapeutic-dose heparin compared to usual care pharmacological thromboprophylaxis in patients hospitalized with community-acquired pneumonia CAP. The study focuses on the high incidence of hospitalizations due to CAP, which often leads to serious complications including thrombotic events that affect respiratory, cardiac, and other organs. This trial aims to explore whether therapeutic-dose heparin can improve outcomes by targeting inflammatory and thrombotic pathways, a strategy shown to help in COVID-19 but not yet studied in non-COVID-19 CAP. Participants are randomly assigned to one of two groups. One group receives therapeutic-dose low molecular-weight heparin LMWH or unfractionated heparin UFH daily for up to 14 days or until hospital discharge, whichever comes first. The other group receives the usual care thromboprophylaxis dose according to local practice, which is lower than the therapeutic dose. Treatments start as soon as possible after randomization. LMWH is preferred unless contraindicated, with dosing based on patient weight, while UFH may be used in cases of renal impairment. During the study, participants will be monitored for outcomes including survival at 30 days, bleeding events, thrombotic events, mechanical ventilation use, mortality at various timepoints, hospital-free days, and health-related quality of life. The study collects data up to 180 days after treatment. Safety monitoring includes tracking adverse events like bleeding and heparin-induced thrombocytopenia. Participation involves hospital stays expected to last at least 72 hours from randomization, with assessments throughout the treatment period and follow-up extending to 180 days.

Age: 18Years +All GendersPhase 3
68 locations
E

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the safety and immune response of a group B streptococcus GBS vaccine in healthy pregnant women and their babies. This Phase 3 randomized, placebo-controlled, double-blinded study involves pregnant participants aged 49 or younger between 24 and 36 weeks of pregnancy, without major fetal abnormalities or infections such as HIV, syphilis, or hepatitis B. The study aims to understand how the GBS vaccine works and its safety profile for both mothers and infants. Participants will receive a single injection of either a multivalent GBS vaccine GBS6 or a placebo saline. After birth, a subset of infants will participate for up to 19 months, receiving standard vaccines including diphtheria toxoid-containing and pneumococcal vaccines as per local immunization schedules. Blood samples will be collected from infants after completing primary and booster vaccinations to assess immune responses. Pregnant participants will attend at least 3 to 4 visits with some allowed by telephone, with follow-up continuing for up to six months after delivery. Infants will be monitored for about 12 months, including a subset with extended follow-up to 19 months. Researchers will evaluate adverse events, antibody levels, and immune responses in both mothers and infants to assess safety and potential protection provided by the vaccine.

Age: 1Day - 49YearsAll GendersPhase 3
219 locations
B

Actively Recruiting

Researchers are conducting the BRAVO study, a multicenter observational research project focused on adults aged 18 and over living with HIVAIDS across Brazil. The study aims to gather detailed information about chronic non-communicable diseases NCDs, mental health, and quality of life in this population to help develop better health policies. It includes participants from various regions in Brazil and emphasizes the importance of understanding cardiometabolic health, mental health, and other risk factors among people living with HIVAIDS. The study collects a wide range of data including sociodemographic details, risk factors for main NCDs, physical examination results, and biological samples for biochemical and metabolic testing. It uses validated tools and some project-developed questionnaires to assess conditions such as depression, anxiety, substance use, and quality of life through the WHOQOL-BREF survey. Data are managed using REDCap software and cover clinical lab tests, physical measures, respiratory function, renal, hepatic, and bone health, as well as sexually transmitted infections and cancer risk assessments. Participants will provide informed consent and undergo a cross-sectional baseline assessment during 2025 and 2026. Researchers will measure the prevalence of chronic diseases, mental disorders, metabolic and behavioral risk factors, antiretroviral therapy adherence, and quality of life at baseline and one year later. The study plans subgroup analyses for specific populations and ensures confidentiality and ethical compliance. Participation involves data collection through questionnaires, exams, and sample collection, with a target of 743 participants to ensure reliable results.

Age: 18Years +All Genders
9 locations
C

Actively Recruiting

Researchers are evaluating two different chemotherapy regimens following long-course chemoradiation therapy for patients with distal rectal cancer. The study aims to compare fluoropyrimidine alone versus fluoropyrimidine combined with oxaliplatin in consolidation chemotherapy to determine their effect on tumor response and the potential for organ preservation through a Watch and Wait strategy. This multi-center trial focuses on patients with MRI-defined distal rectal tumors classified as mrT2-3N0-1 and assesses tumor response after 12 weeks from radiotherapy completion. Participants receive 54 Gy of radiotherapy with daily capecitabine during treatment, followed by consolidation chemotherapy starting one week after radiotherapy ends. One group receives fluoropyrimidine alone, while the other receives fluoropyrimidine plus oxaliplatin, with dosing schedules of either mFOLFOX6 or CAPOX over approximately 12 weeks. Tumor response is centrally reviewed at 12 and 18 weeks, with decisions about continuing organ preservation or proceeding to surgery made by a central committee blinded to treatment assignment. Throughout the study, participants undergo clinical exams, endoscopic assessments, and high-resolution MRI to monitor tumor changes and response. The primary outcome is the decision to proceed with the Watch and Wait approach based on clinical complete response at 18 weeks post-radiotherapy. Secondary outcomes include surgery-free survival, total mesorectal excision-free survival, distant metastases-free survival, local regrowth-free survival, and colostomy-free survival assessed over three years. The study includes ongoing safety monitoring and follow-up to evaluate long-term outcomes.

Age: 18Years +All GendersPhase Not Applicable
24 locations
S

Actively Recruiting

Researchers are evaluating the requirements for four essential amino acids isoleucine, leucine, valine, and tryptophan in neonates who receive total parenteral nutrition TPN. This study will take place at two hospitals in Brazil and aims to better understand how much of each amino acid these stable, TPN-fed preterm babies need. The research uses the Carbon Oxidation method to measure amino acid oxidation and determine the babies nutritional requirements. Each baby will receive one or two levels of either isoleucine, leucine, valine, or tryptophan over a two-day period. On the first day, the baby will receive a standard pediatric amino acid solution along with a labeled bicarbonate to measure carbon dioxide production. On the second day, the baby will receive a test TPN solution with varying amounts of the specific amino acid being studied, including a small amount of labeled phenylalanine to track amino acid oxidation. Breath, urine, and blood samples will be collected to analyze amino acid use and plasma concentrations. During the study, breath and urine samples will be collected to measure amino acid oxidation, and blood samples will be taken alongside routine clinical blood work to assess plasma amino acid levels. The main outcome measured is amino acid oxidation over 48 hours. The study will include stable preterm neonates born at or after 28 weeks gestation, up to 28 days old, who are fully TPN fed. Participation involves close monitoring in the NICU with sample collections coordinated to minimize discomfort.

Age: 1Day - 28DaysAll GendersPhase Not Applicable
1 location

1-10 of 16

1